Clinical research
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
Shares of Minerva Neurosciences are down more than 22% in premarket trading after the company announced late Wednesday that its Phase IIb major depressive disorder (MDD) trial failed to meet primary and key secondary endpoints.
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.
Adamas Pharmaceuticals reported that its Phase III INROADS trial of Gocovri (ADS-5102) for multiple sclerosis (MS) with walking impairment met its primary endpoint. That would seem to be good news, but the trial failed to meet secondary measures which worried investors, causing shares to drop by 45%.
Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.
The trial met its primary efficacy endpoint and all tested secondary endpoints.
GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
The two trials were evaluating the drug for reducing the rate of moderate-to-severe exacerbations compared to placebo over a 52-week period for inadequately controlled moderate-to-severe asthma (GINA Steps 4 and 5).
PRESS RELEASES